LY3316531

LY3316531 is an investigational monoclonal antibody developed by Eli Lilly for the treatment of psoriasis. It has been studied in both healthy participants and patients with psoriasis, administered via subcutaneous or intravenous routes. The drug’s primary mechanism of action is believed to be the neutralization of calcitonin gene-related peptide (CGRP), as evidenced by clinical trial protocols assessing its effect on capsaicin-induced dermal blood flow—a process mediated by CGRP. The molecule is classified as a new molecular entity and falls under the antipsoriatic class, though its precise mechanism remains officially undefined in public sources[2][5][7]. Clinical development appears to have reached Phase 1, with no recent reports indicating further advancement[2][3].

Other names

LY 3316531LY3316531LY-3316531